McKesson transformation supports earnings growth as valuation stays below historical median

Traders Union
All News
Stocks
McKesson earnings growth outlook

Highlights

McKesson raises fiscal 2027 adjusted earnings guidance to $45.60–$46.40 per share, projecting 17%–19% growth driven by oncology and technology segments.
Second-quarter free cash flow surges to $2.9 billion, with first-half free cash flow up 131% year over year to $2.6 billion, and a buyback target of $5 billion for the fiscal year.
Despite over 30% gain in 2026, McKesson trades at approximately 23 times fiscal 2027 midpoint EPS estimate, below its five-year historical median of 25.3 times.

Portfolio shift and earnings outlook

As reported by CNBC, McKesson is building a broader healthcare services and technology model as it expands in oncology, biopharma services, infusion therapy and medical technology. That strategy is gaining traction as the company lifts fiscal 2027 adjusted earnings guidance to $45.60 to $46.40 per share from $44.20 to $45.00, implying growth of 17% to 19%.

Second-quarter results on Nov. 4 underline how the profit mix is changing. Oncology and technology operations account for about 15% of revenue in the quarter, but generate nearly 37% of adjusted segment operating profit, giving McKesson more leverage than its traditional wholesale business.

Portfolio changes are accelerating that shift. McKesson completes its acquisition of Precision Medicine Group on Nov. 2, agrees on Oct. 6 to invest $1.4 billion for a 49% stake in Option Care Health alongside Clayton, Dubilier & Rice, and plans to separate Medical-Surgical Solutions as Wellverse, with an initial public offering expected in the second half of 2027.

Management also announces an agreement in principle to extend McKesson's pharmaceutical distribution partnership with CVS Health through June 2032. If finalized, the extension gives longer-term visibility on a major customer relationship and removes a potential overhang for investors.

Valuation case and sector risks

McKesson remains the largest of the three major U.S. drug wholesalers, supplying pharmacies, hospitals and clinics through a scale-driven distribution network that is difficult to replicate. Demand is supported by an aging population, higher prescription volumes and a pipeline increasingly weighted toward specialty medicines that require more complex handling and patient support.

The company says growth is broad-based across prescription volumes, specialty products and GLP-1 medicines, while cash generation remains strong. Free cash flow reaches about $2.9 billion in the second quarter, first-half free cash flow rises 131% year over year to $2.6 billion, and McKesson expects $4.5 billion to $4.9 billion in free cash flow for full fiscal 2027.

Capital returns are adding to per-share growth, with about $3.4 billion of stock repurchased in the first half and a full-year buyback target of $5 billion. A 15% dividend increase approved in the first quarter further supports shareholder returns.

Even after a gain of more than 30% in 2026, the stock trades at about 23 times the midpoint of fiscal 2027 adjusted earnings guidance, below its roughly 25.3 times five-year historical median. That leaves room for further expansion if earnings continue to rise, although investors still face risks tied to regulation, CVS contract completion, opioid liabilities, thin distribution margins and execution on the company's portfolio changes.

We have also discussed the broader context around FTSE 100 rallying as healthcare and energy shares lifted London equities ahead of key UK and U.S. data.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.